



## Research paper

## Multilocus evaluation of genetic predictors of multiple sclerosis

Yanina Timasheva<sup>a,b,c,\*</sup>, Timur R. Nasibullin<sup>a</sup>, Ilsiyyar A. Tuktarova<sup>a</sup>, Vera V. Erdman<sup>a</sup>,  
Timur R. Galiullin<sup>d</sup>, Oksana V. Zaplakhova<sup>c,d</sup>, Klara Z. Bakhtiarova<sup>c</sup>

<sup>a</sup> Institute of Biochemistry and Genetics of Ufa Federal Research Centre of Russian Academy of Sciences, 71 October Avenue, 450054 Ufa, Russia

<sup>b</sup> Section of Genomics of Common Disease, Department of Medicine, Imperial College London, Hammersmith Hospital Campus, Burlington Danes Building, Du Cane Road, London W12 0NN, United Kingdom

<sup>c</sup> Bashkir State Medical University, 3 Lenin Street, 450008 Ufa, Russia

<sup>d</sup> G. G. Kuvatov Republic Clinical Hospital, 132 Dostoevsky Street, 450005 Ufa, Russia

## ARTICLE INFO

## Keywords:

Multiple sclerosis  
Genome-wide association signals  
Rs3129934  
Human leukocyte antigen  
Major histocompatibility region

## ABSTRACT

**Background:** Genome-wide association studies identified numerous susceptibility loci for multiple sclerosis in populations of European ancestry, but the associations are not always reproducible in other populations due to admixture and different linkage disequilibrium patterns obscuring true association signals.

**Objective:** Our aim was to identify genetic predictors of multiple sclerosis in three ethnically homogenous populations from the Volga-Ural region of Russian Federation.

**Methods:** In the largest to date study of multiple sclerosis in Russian population, involving 2048 participants from the Republic of Bashkortostan, Russian Federation (641 patients with multiple sclerosis and 1407 unaffected individuals), we performed replication analysis of previously identified genome-wide signals for multiple sclerosis. Associations were tested using logistic regression analysis under additive genetic model adjusted for sex. Meta-analysis of the study results in three populations was performed under fixed effects and random effects models.

**Results:** We demonstrate the association with multiple sclerosis of the five variants (*INAVA* rs7522462, *EOMES* rs11129295, *C6orf10* rs3129934, *CD86* rs9282641, and *GPR65* rs2119704). The strongest association (OR = 2.16, CI: 1.85–2.74,  $P = 2.53 \times 10^{-13}$ ) was detected for rs3129934 polymorphism in the major histocompatibility region. Multilocus analysis has revealed 322 and 27 allelic patterns associated with multiple sclerosis in women and men, respectively. In women, the highest risk of MS was conferred by *C6orf10* rs3129934\*T/T + *STAT3* rs744166\*T combination (OR = 11.87), in men – by *C6orf10* rs3129934\*T + *EOMES* rs11129295\*C + *RPS6KB1* rs180515\*C combination (OR = 3.25).

**Conclusion:** We confirm five associations with multiple sclerosis previously reported in genome-wide scans in Europeans in three ethnic groups from the Volga-Ural region of Russia.

## 1. Introduction

Multiple sclerosis (MS) is a complex disease with well-established genetic component. Genome-wide association studies (GWAS) have identified over 700 genetic variants associated with MS ([https://www.ebi.ac.uk/gwas/efotraits/EFO\\_0003885](https://www.ebi.ac.uk/gwas/efotraits/EFO_0003885)), predominantly in populations of European ancestry. The earliest MS GWAS employing family-

based approach (1003 trios in the discovery set, 931 in the replication sample), reported associations with MS reaching the GWAS significance level for two single nucleotide polymorphisms (SNPs), rs3135388 at *HLA-DRA* and rs12722489 at *IL12RA* (Hafler et al., 2007). The recent study totaling 47,429 MS patients and 68,374 control subjects has identified 26,395 SNPs significantly associated with MS (Patsopoulos et al., 2019).

**Abbreviations:** CI, confidence interval; dNTP, deoxynucleoside triphosphate; eQTL, expression quantitative trait locus; FDR, false discovery rate; GWAS, genome-wide association study; IMSCG, International Multiple Sclerosis Genetics Consortium; LD, linkage disequilibrium; MAF, minor allele frequency; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; MS, multiple sclerosis; OR, odds ratio; PCR, polymerase chain reaction; RF, Russian Federation; SNP, single nucleotide polymorphism; WTCCC2, Wellcome Trust Case Control Consortium 2.

\* Corresponding author at: Institute of Biochemistry and Genetics of Ufa Federal Research Centre of Russian Academy of Sciences, 71 October Avenue, 450054 Ufa, Russia.

E-mail address: [y.timasheva@imperial.ac.uk](mailto:y.timasheva@imperial.ac.uk) (Y. Timasheva).

<https://doi.org/10.1016/j.gene.2021.146008>

Received 11 June 2021; Received in revised form 5 August 2021; Accepted 11 October 2021

Available online 14 October 2021

0378-1119/© 2021 Elsevier B.V. All rights reserved.

It has been reported that the clinical course of MS can vary among different ethnic groups (Cree et al., 2004). The disease prevalence also shows distinct ethno-geographic patterns with the highest estimates per 100,000 population registered in North America (average 164.6, in Canada 291.0), Western Europe (average 127.0, in Denmark 227.0), and Australasia (91.1), and the lowest in eastern sub-Saharan Africa (3.3), central sub-Saharan Africa (2.8), and Oceania (2.0) (G. B. D. Multiple Sclerosis Collaborators, 2016; Browne et al., 2014). The evidence from GWAS supports the existence of population-specific patterns of MS heritability. For example, the major histocompatibility complex (MHC) region on chromosome 6 has been strongly and consistently associated with MS across ethnicities (Hafler et al., 2007; Comabella et al., 2008; De Jager et al., 2009; Bahlo et al., 2009; Jakkula et al., 2010; Sanna et al., 2010; Nischwitz et al., 2010; Patsopoulos et al., 2011; Martinelli-Boneschi et al., 2012; Andlauer et al., 2016). However, fine-mapping of the GWAS signals reveals a linkage disequilibrium (LD) block ( $r^2 = 0.9-1.0$ ) containing SNPs (rs3135388, rs3129889, rs9271366, and rs3104373) associated with MS in Caucasian populations from the United Kingdom (UK), United States (US), Australia, New Zealand, Germany, Switzerland, and the Netherlands, (Hafler et al., 2007; De Jager et al., 2009; Bahlo et al., 2009; Nischwitz et al., 2010; Patsopoulos et al., 2011; Andlauer et al., 2016) and highlights distinct variants associated with MS exclusively in Spanish and Italian populations (rs3129934), (Comabella et al., 2008; Martinelli-Boneschi et al., 2012) in Finns (rs3135338), (Jakkula et al., 2010) and Sardinians (rs2040406) (Sanna et al., 2010). Furthermore, populations of non-European ancestry are currently underrepresented in GWAS, and limited data exist on the reproducibility of the GWAS findings. Additional challenge in interpreting GWAS results lies in detecting interactions between the established loci that may lead to interindividual differences in susceptibility to MS.

Populations of the Volga-Ural region of Russia are an interesting object for genetic study due to the unique combination of European and Asian genetic ancestry. The aim of our study was to perform the replication analysis of previously identified GWAS signals for MS and to identify complex genetic markers of MS in a group of patients with MS and non-affected individuals from three ethnic groups originating from the Republic of Bashkortostan (Russian Federation).

## 2. Materials and methods

### 2.1. Study group

The study was conducted in accordance with the principles for medical research involving human subjects outlined in the Declaration of Helsinki of the World Medical Association (2000). Written informed consent was provided by all participants. The protocol of the study was approved by the ethics committee of the Institute of Biochemistry and Genetics of Ufa Federal Research Centre of Russian Academy of Sciences (No.1/28.10.2007).

The group of patients was composed of persons registered at the Republic Multiple Sclerosis Centre (RMSC). RMSC has recorded data on 1145 patients with MS; 641 were enrolled in the study (427 women, mean age  $40.04 \pm 9.6$  yrs, and 214 men, mean age  $41.28 \pm 10.69$  yrs). Control group was comprised of 1407 healthy subjects (708 women, mean age  $38.08 \pm 11.06$  yrs; 699 men, mean age  $37.48 \pm 10.71$  yrs) without neurodegenerative or other chronic diseases. Ethnic origin was established according to the data from questionnaire containing questions about ethnicity and the place of birth of the ancestors in three generations. All individuals included in study permanently resided in the Republic of Bashkortostan and belonged to Bashkir ( $n = 325$ ), Russian ( $n = 772$ ), or Tatar ( $n = 951$ ) ethnic group. Persons of mixed ancestry were excluded from genotyping.

MS was diagnosed according to the McDonald criteria (2010). Expanded Disability Status Scale was used to assess the severity of MS. The disease progression rate was calculated by dividing the EDSS score

by the duration of MS in years. Clinical characteristics of the group of patients are provided in Table 1. Healthy controls were recruited at the Republic Centre of Blood Transfusion (Ufa, Republic of Bashkortostan, Russian Federation).

### 2.2. Genotyping

Whole venous blood was collected from each participant and stored at  $-4^\circ\text{C}$ . Total DNA was isolated from 6 ml of whole venous blood using standard extraction protocol. The DNA quality was assessed by electrophoresis in 0.8% agarose gel and quantified by ultraviolet absorbance spectrophotometry analysis. Genotyping was performed using PCR with subsequent restriction endonuclease digestion (rs3129934, rs4410871) or PCR with allele-specific assays (all other SNPs). Primers were designed using PrimerSelect 5.05 software (DNASar Inc., Madison, WI, USA) (Supplementary Table S1). SNPs for the analysis were selected according to the following criteria: previously reported GWAS associations with MS or other autoimmune traits, known or suggested functional significance, minor allele frequency  $> 0.05$  in European populations according to the Ensembl database (Yates et al., 2019).

DNA sequences for the primer design were retrieved from NCBI (National Center for Biotechnology Information) database (<http://www.ncbi.nlm.nih.gov/SNP>). The concentrations of primers and probe were optimised leading to the following PCR conditions: 0.2 mM of both primers, 20 ng of DNA template, 30 mM Tris-HCl (pH 8.6/25C), 16.6 mM  $(\text{NH}_4)_2\text{SO}_4$ , 2.5MgCl<sub>2</sub> 0.2 mM of each dNTPs (Thermo Fisher Scientific, Lithuania), and 0.5 U of Taq-polymerase enzyme. The amplification was performed in a T100™ thermal cycler (BioRad, USA) programmed for initial denaturation step ( $95^\circ\text{C}$  for 1 min) followed by 28 cycles of amplification (denaturation at  $95^\circ\text{C}$  for 20 s, primer annealing at specific temperature for 30 s, elongation at  $72^\circ\text{C}$  for 30 s) and a final extension ( $72^\circ\text{C}$  for 4 min). Restriction analysis for rs3129934 and rs4410871 polymorphisms was performed by incubating 10  $\mu\text{l}$  of PCR product in a 20  $\mu\text{l}$  reaction volume at  $37^\circ\text{C}$  for 16 h with 10 U of restriction endonuclease (*Rsr2I* and *HindIII*, respectively). PCR and restriction products were separated by electrophoresis in 2% agarose gel and identified using Mega-Bioprint 1100 gel documentation system (Vilber Lourmat, Collégien, France). As quality control, 5% of the

**Table 1**

Clinical characteristics of the group of patients with multiple sclerosis.

Parameters	Bashkirs	Russians	Tatars
Age (M $\pm$ SD), years	40.28 $\pm$ 9.86	40.6 $\pm$ 9.77	40.89 $\pm$ 9.75
Sex (% women)	66.0	66.8	66.7
Age of disease onset (M $\pm$ SD), years	27.93 $\pm$ 7.76	27.64 $\pm$ 8.9	27.53 $\pm$ 8.89
Disease duration (M $\pm$ SD), years	12.4 $\pm$ 8.65	13.17 $\pm$ 9.53	13.36 $\pm$ 9.93
Types of multiple sclerosis (%):			
relapsing-remitting	30.1	36.9	43.7
primary-progressive	15.1	10.2	15.6
secondary-progressive	54.8	52.9	40.7
Clinical symptoms (%):			
sensory impairments	16.5	17.1	12
oculomotor dysfunction	6.5	4.9	4.4
movement dysfunction	23.1	35	29.8
coordination loss	22	18.6	18.7
combined movement and coordination difficulties	12.1	4.2	6.4
symptoms of cranial nerve lesions	4.4	2.7	2.8
retrobulbar neuritis	11	14.4	19.9
others	4.4	3.1	6
EDSS (M $\pm$ SD)	4.9 $\pm$ 2.39	4.41 $\pm$ 1.56	4.46 $\pm$ 1.77
Progression rate (M $\pm$ SD), step/year	0.74 $\pm$ 1.05	0.73 $\pm$ 1.09	0.69 $\pm$ 0.89

M – mean value, SD – standard deviation, EDSS – Expanded Disability Status Scale.

genotyped samples were randomly selected for re-genotyping, and all newly obtained results were identical to the previously determined genotyping data.

### 2.3. Statistical analysis

The study data were stored and managed using IBM SPSS Statistics V22.0 (Chicago, IL, USA). All SNPs were tested for compliance with Hardy-Weinberg equilibrium in the control group (Table 2).

Associations between the studied SNP and MS were analysed separately in each group using logistic regression analysis under additive genetic model adjusted for sex implemented in PLINK software (<http://pngu.mgh.harvard.edu/purcell/plink/>) (Purcell et al., 2007). Additive model assumes that there is a linear gradient in risk between the homozygotes for the non-effect allele, heterozygotes, and homozygotes for the effect allele. The effect allele was determined according to the GWAS results in European populations (De Jager et al., 2009; Bahlo et al., 2009; Jakkula et al., 2010; Sawcer et al., 2010)\*\*\*\*. Meta-analysis of the study results was performed under fixed effects and random effects models. P values of <0.05 were considered statistically significant. Correction for multiple testing was performed using the false discovery rate (FDR) method (Benjamini and Hochberg, 1995).

Multilocus analysis of association between allelic combinations of the studied loci and MS was performed using APSampler 3.6.0/ (the program and its description can be accessed at <http://apsampler.sourceforge.net/>). APSampler (Allelic Pattern Sampler) applies a Markov chain Monte Carlo method based on Bayesian approaches to identify combinations of allelic variants of multiple loci associated with the studied trait (Favorov et al., 2005). Since APSampler program does not allow for adjustment for potential confounders, including sex, the analysis was performed separately for men and women.

## 3. Results

### 3.1. Single locus analysis

The observed genotype frequencies of all studied SNPs among the control subjects were in agreement with Hardy-Weinberg equilibrium (Table 2). Testing the associations between the studied loci and MS in the three populations separately, we detected the association of *C6orf10* rs3129934\*T and *EOMES* rs11129295\*T alleles with the disease in the Russian and Tatar ethnic groups (Table 3).

### 3.2. Meta-analysis in the three ethnic groups

Meta-analysis of the study results in all three groups under the random effects model revealed the associations of the *INAVA* rs7522462\*G, *EOMES* rs11129295\*T, *CD86* rs9282641\*G, *C6orf10* rs3129934\*T, and *GPR65* rs2119704\*C alleles with MS (Table 4). Comparing the results of our replication meta-analysis with the data obtained in the initial GWAS, we found that the directions of the observed associations were consistent with the previously identified for all loci, except for rs7522462 at *INAVA* (Table 4). Our data shows that *INAVA* rs7522462\*G allele confers decreased risk of MS (OR = 0.74,  $P_{FDR} = 1.25 \times 10^{-3}$ ), while the findings of the International Multiple Sclerosis Genetics Consortium (IMSGC) indicate that in Europeans, this allele is associated with the increased risk of MS (Sawcer et al., 2011).

The effect allele frequencies in the three Russian populations and in five global super populations (according to the 1000 Genomes Project Phase 3 ([http://www.ensembl.org/Homo\\_sapiens/Variation/Population](http://www.ensembl.org/Homo_sapiens/Variation/Population))) are shown in Table 4.

## 4. Multilocus analysis

Using APSampler program, we identified 322 allelic patterns significantly associated with MS in women, and 27 – men (Supplementary Tables S2 and S3). The allele/genotype combinations conferring the most potent risk of MS ( $0.3 \geq OR \geq 3.0$ ) are presented in Table 5. Among them, most commonly featured were *C6orf10* rs3129934 and *SOX8* rs2744148 alleles/genotypes (11 combinations), followed by *IL7RA* rs6897932 (8), and *INAVA* rs7522462 (6). *EOMES* rs11129295 and *GPR65* rs2119704 were present in 5 patterns each, *RGS1* rs1323292 and *CD58* rs2300747 in 3, *PVT1* rs4410871 and *RPS6KB1* rs180515 – in 3, *STAT3* rs744166 and *ZBTB46* rs6062314 – in 2, while *CD86* rs9282641, *MANBA* rs228614, *TNFRSF1A* rs1800693, and *CD40* rs6074022 appeared only once.

Notably, the majority of the studied loci demonstrated the change in the direction of the observed associations (Supplementary Tables S2 and S3), with the only exception being *C6orf10* rs3129934 – its T allele invariably conferred the increased risk of MS, while C allele and C/C genotype was present in the combinations with beneficial effect towards MS. The highest risk of MS in women was conferred by *C6orf10* rs3129934\*T/T genotype in combination with *STAT3* rs744166\*T (OR = 11.87) and *CD58* rs2300747\*A allele (OR = 10.98), in men – by *C6orf10* rs3129934\*T allele together with *EOMES* rs11129295\*C and *RPS6KB1* rs180515\*C alleles (OR = 3.25).

**Table 2**

The list of the studied loci, minor allele frequencies, and the results of testing for Hardy-Weinberg equilibrium in the three ethnic groups.

Chr	Locus	SNP	MA	Bashkirs		Russians		Tatars	
				MAF	P-value	MAF	P-value	MAF	P-value
1	<i>RGS1</i>	rs1323292	G	0.16	0.127	0.18	0.594	0.17	0.135
1	<i>CD58</i>	rs2300747	G	0.31	1	0.16	0.418	0.22	0.737
1	<i>INAVA</i>	rs7522462	A	0.18	0.114	0.23	0.121	0.24	0.340
3	<i>EOMES</i>	rs11129295	T	0.43	0.161	0.37	0.710	0.41	0.138
3	<i>CD86</i>	rs9282641	A	0.04	1	0.05	1	0.05	0.307
4	<i>MANBA</i>	rs228614	G	0.49	1	0.47	0.642	0.49	0.716
5	<i>IL7RA</i>	rs6897932	T	0.23	0.788	0.25	0.884	0.25	1
6	<i>C6orf10</i>	rs3129934	T	0.13	1	0.16	0.714	0.14	1
8	<i>PVT1</i>	rs4410871	T	0.31	0.207	0.25	0.396	0.26	1
12	<i>TNFRSF1A</i>	rs1800693	G	0.45	0.714	0.50	0.914	0.48	1
14	<i>GPR65</i>	rs2119704	A	0.06	1	0.07	1	0.07	0.704
16	<i>SOX8</i>	rs2744148	G	0.14	0.692	0.17	1	0.14	0.404
17	<i>STAT3</i>	rs744166	C	0.38	0.707	0.41	0.122	0.39	0.309
17	<i>RPS6KB1</i>	rs180515	C	0.37	0.436	0.37	0.127	0.41	0.619
20	<i>CD40</i>	rs6074022	C	0.27	0.0942	0.25	0.776	0.29	0.884
20	<i>ZBTB46</i>	rs6062314	C	0.04	0.141	0.10	0.771	0.06	1

Chr – chromosome, SNP – single nucleotide polymorphism, MA – minor allele, N – number of individuals with non-missing genotyping data, MAF – minor allele frequency in the control group, P-value – P-value for Hardy-Weinberg equilibrium in controls

**Table 3**

Results of the analysis of association of the studied loci with the risk of multiple sclerosis.

Locus	SNP	EA	Bashkirs			Russians			Tatars		
			OR (CI)	P	P <sub>FDR</sub>	OR (CI)	P	P <sub>FDR</sub>	OR (CI)	P	P <sub>FDR</sub>
<i>RGS1</i>	rs1323292	A	1.06 (0.65–1.76)	0.808	0.864	1.21 (0.89–1.64)	0.226	0.452	0.85 (0.62–1.18)	0.338	0.499
<i>CD58</i>	rs2300747	G	0.84 (0.54–1.32)	0.457	0.732	0.97 (0.70–1.34)	0.854	0.945	0.72 (0.52–1.01)	0.054	0.172
<i>INAVA</i>	rs7522462	G	0.69 (0.43–1.12)	0.136	0.545	0.70 (0.53–0.92)	0.010	0.053	0.82 (0.61–1.08)	0.159	0.318
<i>EOMES</i>	rs11129295	T	1.22 (0.82–1.80)	0.330	0.677	1.56 (1.21–2.00)	6.03x10 <sup>-4</sup>	4.83x10 <sup>-3</sup>	1.48 (1.14–1.92)	0.003	0.026
<i>CD86</i>	rs9282641	G	0.36 (0.13–1.04)	0.059	0.531	1.94 (1.06–3.55)	0.032	0.128	2.04 (1.10–3.80)	0.024	0.096
<i>MANBA</i>	rs228614	G	1.38 (0.92–2.05)	0.115	0.545	0.91 (0.71–1.17)	0.453	0.652	1.02 (0.78–1.33)	0.886	0.945
<i>IL7RA</i>	rs6897932	C	0.77 (0.49–1.22)	0.264	0.677	1.00 (0.75–1.34)	0.977	0.977	1.12 (0.82–1.52)	0.485	0.647
<i>C6orf10</i>	rs3129934	T	1.41 (0.15–12.93)	0.764	0.864	2.00 (1.51–2.65)	1.58x10 <sup>-6</sup>	2.53x10 <sup>-5</sup>	2.38 (1.75–3.22)	2.33x10 <sup>-8</sup>	3.72x10 <sup>-7</sup>
<i>PVT1</i>	rs4410871	C	1.05 (0.69–1.60)	0.810	0.864	1.29 (0.97–1.72)	0.076	0.244	1.05 (0.78–1.41)	0.762	0.897
<i>TNFRSF1A</i>	rs1800693	G	1.11 (0.76–1.63)	0.580	0.843	1.02 (0.80–1.29)	0.886	0.945	1.22 (0.95–1.58)	0.116	0.266
<i>GPR65</i>	rs2119704	C	2.66 (0.94–7.57)	0.066	0.531	1.47 (0.91–2.38)	0.118	0.314	1.53 (0.92–2.56)	0.103	0.266
<i>SOX8</i>	rs2744148	G	1.39 (0.81–2.39)	0.234	0.677	1.12 (0.82–1.52)	0.489	0.652	1.20 (0.84–1.73)	0.313	0.499
<i>STAT3</i>	rs744166	T	0.92 (0.61–1.39)	0.685	0.864	1.04 (0.81–1.34)	0.760	0.936	0.96 (0.74–1.25)	0.785	0.897
<i>RPS6KB1</i>	rs180515	C	0.98 (0.64–1.50)	0.917	0.917	1.19 (0.92–1.52)	0.179	0.409	1.01 (0.78–1.31)	0.959	0.959
<i>CD40</i>	rs6074022	C	1.20 (0.77–1.87)	0.428	0.732	0.86 (0.66–1.12)	0.267	0.474	0.88 (0.67–1.15)	0.343	0.499
<i>ZBTB46</i>	rs6062314	T	0.64 (0.25–1.60)	0.339	0.677	1.23 (0.82–1.86)	0.319	0.510	2.20 (1.19–4.09)	0.012	0.065

EA – effect allele, OR – odds ratio, CI – 95% confidence interval, P – P-value, P<sub>FDR</sub> – significance level corrected for multiple testing using Benjamini–Hochberg procedure. The OR is aligned to the effect allele as reported in the discovery study. Statistically significant associations are shown in bold

## 5. Discussion

We performed the replication analysis of the 16 GWAS-derived risk loci for MS in three ethnic populations from the Republic of Bashkortostan (Russian Federation), and confirmed the association of five SNPs with the disease (Table 4). Four of these loci (*INAVA* rs7522462, *EOMES* rs11129295, *CD86* rs9282641, and *GPR65* rs2119704) were initially identified in GWAS performed as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2) project, with European ancestry cases recruited through IMSGC in 15 countries (Finland, Sweden, Norway, Denmark, Australia, New Zealand, United Kingdom, Germany, Belgium, Poland, Ireland, USA, France, Spain, and Italy), and WTCCC2 common control set (Sawcer et al., 2011). The effect allele frequencies observed in the studied ethnic groups were largely similar to European populations (Table 4).

*C6orf10* rs3129934 polymorphism is located in near the *HLA-DRB1/DQA* region, and its association with MS was first reported in the GWAS conducted in Spanish population (242 cases, 242 controls) with subsequent replication in 1586 individuals from Spain and the U.S (Comabella et al., 2008). This association was confirmed in a later GWAS in Italian population with replication in Australian and Northern Europe collections (Martinelli-Boneschi et al., 2012). In our study, rs3129934\*T allele was consistently associated with higher MS risk in the Russian and Tatar ethnic groups when analysed separately, in all three populations according to the meta-analysis results, and as part of the genotype/allele combinations conferring increased risk of MS.

The rs11129295 polymorphism is located in the intergenic region near *EOMES* gene encoding for eomesodermin, a transcription factor from the T-box family. Eomesodermin activates interleukin 10 expression, driving the differentiation of type 1 regulatory T cells that are critical for the prevention of graft-versus-host disease, and thus plays an immunoregulatory role (Gruarin et al., 2019). It also promotes the differentiation of CD8 + memory T cells responsible for the development of immunological memory, providing protection against subsequent infection with the same pathogen following the initial immune response (Reiser et al., 2019). Transcriptional activity of *EOMES* gene was downregulated in untreated MS patients, and rs11129295 was an eQTL for *EOMES* in the peripheral blood (Parnell et al., 2014). Another study established heritability of *EOMES* expression in twins, and observed lower levels of *EOMES* expression in patients on fingolimod and interferon beta compared to untreated patients (McKay et al., 2016). T allele of the rs11129295 was associated with increased risk of relapsing-remitting MS in the Chinese population (Chen et al., 2018). *EOMES* rs11129295 is also in linkage disequilibrium with SNPs associated with

MS (rs2371108,  $r^2 = 0.86$ ) and other autoimmune diseases, such as chronic lymphocytic leukemia (rs9880772,  $r^2 = 0.72$ ), rheumatoid arthritis and Hodgkin's lymphoma (rs3806624,  $r^2 = 0.7$ ), ankylosing spondylitis (rs13093489,  $r^2 = 0.91$ ) (Beecham et al., 2013; Cortes et al., 2013).

Polymorphism rs7522462 is located in the innate immunity activator (*INAVA*) locus on chromosome 1, also known as open reading frame 106 (*C1orf106*). This SNP is in tight linkage disequilibrium with two other MS markers: rs55838263 ( $r^2 = 0.98$ ) and rs59655222 ( $r^2 = 0.995$ ), also associated with celiac disease, (Patsopoulos et al., 2019; Beecham et al., 2013) and is also linked with SNPs associated with various autoimmune disorders: Crohn's disease (rs7554511,  $r^2 = 0.995$ ; rs11584383,  $r^2 = 0.8$ ), ulcerative colitis (rs7554511,  $r^2 = 0.95$ ), inflammatory bowel disease (rs7554511,  $r^2 = 0.95$ ; rs35730213,  $r^2 = 0.99$ ); ankylosing spondylitis (rs41299637,  $r^2 = 0.995$ ; rs2297909,  $r^2 = 0.78$ ), celiac disease (rs10800746,  $r^2 = 0.91$ ) (Cortes et al., 2013). Notably, rs7554511\*C allele was correlated with rs7522462\*G allele ( $r^2 = 0.995$ ), and rs7554511\*C allele carriers demonstrated lower *INAVA* expression and decreased cytokine production in macrophages (Yan et al., 2017).

*INAVA* expression was upregulated in tumor cells, and was correlated with fibroblast growth factor 1 (FGF1) and matrix metalloproteinase 9 (MMP9) levels (Guan et al., 2018). FGF1 is involved in a wide range of biological processes including proliferation, morphogenesis, cell growth, and cell survival. *FGF1* expression is reduced in active MS lesions and increased in remyelinated MS lesions in astrocytes, neurons, oligodendrocytes, microglia, and infiltrating T cells and B cells (Mohan et al., 2014). FGF1 accelerates myelination *in vitro* and might contribute to CNS repair by inducing lipid synthesis by astrocytes and microglia (Berghoff et al., 2017). MMPs are a family of enzymes that are responsible for degrading extracellular matrix proteins, and MMP9 levels were increased in cerebrospinal fluid (CSF) of MS patients, particularly during clinical relapse, presumably due to intrathecal synthesis (Liuzzi et al., 2002). Serum and CSF levels of MMP9 were higher in patients with relapsing-remitting MS than with primary progressive MS or healthy controls (Sastre-Garriga et al., 2004). MMP9 has been studied as a potential therapeutic target for MS treatment. Moreover, treatment by interferon beta reportedly reduced MMP9 activity, subsequently decreasing T-lymphocyte infiltration into central nervous system, while natalizumab infusions lead to the increase in MMP9 plasma levels (Iannetta et al., 2019).

The results of the meta-analysis revealed the association between the common allele rs9282641\*G and increased risk of MS in the three studied populations. This SNP is mapped to *CD86* gene, and the carriers



**Table 4**Results of the replication *meta*-analysis analysis of previously identified genetic markers of multiple sclerosis in three ethnic groups.

Locus	SNP	EA	GWAS		Replication <i>meta</i> -analysis in three Russian populations		EAF							
			OR (CI)	P-value	OR (CI)	P-value	BASH	RUS	TAT	AFR	AMR	EAS	EUR	SAS
<i>RGS1</i>	rs1323292	A	1.12 (1.1–1.14) (Sawcer et al., 2011)	<b>2.3x10<sup>-8</sup></b>	1.03 (0.85–1.27)	0.762	0.842	0.819	0.835	0.980	0.764	0.802	0.815	0.925
<i>CD58</i>	rs2300747	G	0.77 (0.68–0.88) (De Jager et al., 2009)	<b>3.10x10<sup>-10</sup></b>	0.84 (0.69–1.03)	0.097	0.310	0.160	0.220	0.266	0.334	0.594	0.142	0.385
<i>INAVA</i>	rs7522462	G	1.11 (1.1–1.13) (Sawcer et al., 2011)	<b>1.9x10<sup>-9</sup></b>	0.74 (0.62–0.89)	1.43x10 <sup>-3</sup>	0.817	0.769	0.765	0.888	0.844	0.997	0.726	0.874
<i>EOMES</i>	rs11129295	T	1.11 (1.09–1.12) (Sawcer et al., 2011)	<b>1.2x10<sup>-9</sup></b>	1.46 (1.24–1.71)	6.72x10 <sup>-6</sup>	0.430	0.370	0.410	0.335	0.566	0.776	0.386	0.687
<i>CD86</i>	rs9282641	G	1.21 (1.18–1.24) (Sawcer et al., 2011)	<b>1.2x10<sup>-11</sup></b>	1.56 (1.06–2.30)	0.030	0.960	0.949	0.948	0.977	0.916	0.999	0.908	0.908
<i>MANBA</i>	rs228614	G	1.09 (1.07–1.1) (Sawcer et al., 2011)	<b>1.40x10<sup>-7</sup></b>	1.02 (0.86–1.19)	0.808	0.490	0.470	0.490	0.432	0.659	0.499	0.508	0.430
<i>IL7RA</i>	rs6897932	C	1.11 (1.09–1.13) (Sawcer et al., 2011)	<b>1.7x10<sup>-8</sup></b>	1.00 (0.82–1.21)	0.986	0.770	0.752	0.750	0.934	0.817	0.831	0.729	0.788
<i>C6orf10</i>	rs3129934	T	3.30 (2.3–4.9) (Comabella et al., 2008)	<b>9.0x10<sup>-11</sup></b>	2.16 (1.85–2.74)	2.53x10 <sup>-13</sup>	0.126	0.162	0.136	0.222	0.121	0.096	0.142	0.081
<i>PVT1</i>	rs4410871	C	1.11 (1.09–1.12) (Sawcer et al., 2011)	<b>7.7x10<sup>-9</sup></b>	1.15 (0.96–1.39)	0.148	0.689	0.748	0.743	0.858	0.599	0.632	0.693	0.718
<i>TNFRSF1A</i>	rs1800693	G	1.12 (1.11–1.14) (Sawcer et al., 2011)	<b>4.1x10<sup>-14</sup></b>	1.11 (0.95–1.30)	0.194	0.450	0.500	0.480	0.361	0.281	0.123	0.425	0.283
<i>GPR65</i>	rs2119704	C	1.22 (1.19–1.25) (Sawcer et al., 2011)	<b>2.2x10<sup>-10</sup></b>	1.59 (1.13–2.19)	0.006	0.944	0.926	0.926	0.761	0.941	0.804	0.925	0.962
<i>SOX8</i>	rs2744148	G	1.12 (1.1–1.14) (Sawcer et al., 2011)	<b>8.4x10<sup>-8</sup></b>	1.19 (0.95–1.45)	0.120	0.140	0.170	0.140	0.149	0.091	0.013	0.163	0.305
<i>STAT3</i>	rs744166	T	0.87 (0.83–0.91) (Jakkula et al., 2010)	<b>2.75x10<sup>-10</sup></b>	0.99 (0.84–1.17)	0.894	0.622	0.585	0.612	0.281	0.713	0.602	0.585	0.489
<i>RPS6KB1</i>	rs180515	C	1.09 (1.08–1.11) (Sawcer et al., 2011)	<b>8.8x10<sup>-8</sup></b>	1.08 (0.92–1.28)	0.373	0.370	0.370	0.410	0.282	0.316	0.463	0.310	0.335
<i>CD40</i>	rs6074022	C	1.2 (NA) (Bahlo et al., 2009)	<b>1.30x10<sup>-7</sup></b>	0.91 (0.77–1.10)	0.303	0.270	0.250	0.290	0.023	0.212	0.440	0.257	0.268
<i>ZBTB46</i>	rs6062314	T	1.16 (1.14–1.19) (Sawcer et al., 2011)	<b>1.30x10<sup>-7</sup></b>	1.33 (0.98–1.84)	0.080	0.956	0.903	0.942	0.775	0.960	0.992	0.923	0.965

EA – effect allele; OR – odds ratio; CI – 95% confidence interval; EAF – effect allele frequency; BASH – Bashkirs, RUS – Russians, TAT – Tatars, AFR – African, AMR – American, EAS – East Asian, EUR – European, SAS – South Asian; NA – not available. Statistically significant associations are shown in bold.

of rs9282641\*G allele had higher expression of *CD86*, primarily in the naïve B-cells (CD19+/CD27 +) (Smets et al., 2018). Hi-C approach also identified association of the regulatory element containing rs9282641 with *CD86* promoter (Corradin et al., 2016). *CD86* is a costimulatory molecule expressed on B-cells and other antigen-presenting cells, and the percentage of *CD86* + B-cells was significantly increased in the peripheral blood of MS patients (Fraussen et al., 2016). In addition to rs9282641, *CD86* locus harbours three other MS-associated SNPs: rs4308217, rs2255214, and rs2681424, none of which is linked with rs9282641, but rs2255214 and rs2681424, located in the upstream region of *CD86*, are in LD with each other ( $r^2 = 1.0$ ).

Another polymorphism associated with MS according to the results of the *meta*-analysis was rs2119704, located in the *LINC01147* locus, in the downstream region of the *GPR65* gene. This polymorphism was an eQTL for *GPR65* expression in fibroblasts according to the Genotype-Tissue Expression (GTEx) Project data. This gene encodes a glycosphingolipid receptor and its altered expression may affect myelin integrity during the pathogenesis of MS.

The results of the multilocus analysis performed using APSampler show distinctive patterns of association with MS in women and men (Supplementary Tables S1 and S2). The number of allele/genotype combinations associated with MS in women was much larger than in men (322 and 27, respectively), which in part is due to predominance of women among study participants (female-to-male ratio in the group of patients was 2.00, overall – 1.24). In men, *C6orf10* rs3129934 was the core element of the majority of identified patterns ( $N = 20$ ), while in women it was found only in 13 out of 322, and the most commonly featured were *IL7RA* rs6897932 (108 combinations), *SOX8* rs2744148 (88), *CD58* rs2300747 (83), *GPR65* rs2119704 (79), *INAVA* rs7522462 (67), *MANBA* rs228614 (67). Due to overrepresentation of loci with weaker effects, the same alleles and/or genotypes are often included both in predisposing and protective combinations.

## 6. Conclusion

The results of our study confirm the association with multiple

**Table 5**

The allele/genotype combinations most significantly associated with multiple sclerosis.

Pattern	MS	Control	OR	CI(95%)	P	P <sub>FDR</sub>
<b>Women</b>						
<i>C6orf10</i> rs3129934*T/T + <i>STAT3</i> rs744166*T	0.07	0.01	11.87	2.75–51.23	1.67x10 <sup>-5</sup>	1.34x10 <sup>-4</sup>
<i>CD58</i> rs2300747*A + <i>C6orf10</i> rs3129934*T/T	0.07	0.01	10.98	2.53–47.61	4.14x10 <sup>-5</sup>	2.66x10 <sup>-4</sup>
<i>C6orf10</i> rs3129934*T/T	0.06	0.004	5.11	2.14–12.23	8.04x10 <sup>-5</sup>	4.41x10 <sup>-4</sup>
<i>CD58</i> rs2300747*A + <i>EOMES</i> rs11129295*T + <i>IL7RA</i> rs6897932*C + <i>C6orf10</i> rs3129934*T	0.32	0.09	4.87	2.93–8.10	3.24x10 <sup>-11</sup>	1.32x10 <sup>-7</sup>
<i>INAVA</i> rs7522462*A + <i>IL7RA</i> rs6897932*T + <i>SOX8</i> rs2744148*G + <i>ZBTB46</i> rs6062314*T	0.07	0.02	4.82	1.81–12.78	3.56x10 <sup>-4</sup>	1.45x10 <sup>-3</sup>
<i>INAVA</i> rs7522462*A + <i>IL7RA</i> rs6897932*T + <i>SOX8</i> rs2744148*G	0.07	0.02	4.80	1.81–12.74	3.66x10 <sup>-4</sup>	1.48x10 <sup>-3</sup>
<i>RGS1</i> rs1323292*A/A + <i>IL7RA</i> rs6897932*T + <i>SOX8</i> rs2744148*G	0.12	0.03	3.76	1.90–7.46	3.19x10 <sup>-5</sup>	2.17x10 <sup>-3</sup>
<i>EOMES</i> rs11129295*T + <i>IL7RA</i> rs6897932*C + <i>GPR65</i> rs2119704*C/C + <i>SOX8</i> rs2744148*G	0.21	0.07	3.49	2.12–5.74	1.45x10 <sup>-7</sup>	4.70x10 <sup>-6</sup>
<i>CD58</i> rs2300747*A + <i>C6orf10</i> rs3129934*T + <i>GPR65</i> rs2119704*C + <i>ZBTB46</i> rs6062314*T	0.47	0.20	3.46	2.37–5.05	3.19x10 <sup>-11</sup>	2.60x10 <sup>-7</sup>
<i>CD58</i> rs2300747*A + <i>C6orf10</i> rs3129934*T + <i>GPR65</i> rs2119704*C	0.47	0.21	3.36	2.31–4.90	6.32x10 <sup>-11</sup>	1.72x10 <sup>-7</sup>
<i>SOX8</i> rs2744148*G/G + <i>STAT3</i> rs744166*T	0.04	0.01	3.30	1.18–9.26	1.46x10 <sup>-2</sup>	3.26x10 <sup>-2</sup>
<i>INAVA</i> rs7522462*A/A + <i>PVT1</i> rs4410871*C + <i>TNFRSF1A</i> rs1800693*A	0.09	0.03	3.26	1.52–6.98	9.48x10 <sup>-4</sup>	3.28x10 <sup>-3</sup>
<i>RGS1</i> rs1323292*A + <i>IL7RA</i> rs6897932*T + <i>PVT1</i> rs4410871*C + <i>SOX8</i> rs2744148*G	0.14	0.05	3.20	1.78–5.74	2.88x10 <sup>-5</sup>	2.00x10 <sup>-4</sup>
<i>INAVA</i> rs7522462*A + <i>RPS6KB1</i> rs180515*C/C	0.07	0.02	3.19	1.42–7.15	2.25x10 <sup>-3</sup>	6.58x10 <sup>-3</sup>
<i>RGS1</i> rs1323292*A + <i>IL7RA</i> rs6897932*T/C + <i>SOX8</i> rs2744148*G	0.15	0.05	3.07	1.73–5.44	3.85x10 <sup>-5</sup>	2.52x10 <sup>-4</sup>
<i>EOMES</i> rs11129295*T/T + <i>SOX8</i> rs2744148*G	0.08	0.03	3.01	1.39–6.50	2.48x10 <sup>-3</sup>	7.41x10 <sup>-3</sup>
<i>RGS1</i> rs1323292*A + <i>IL7RA</i> rs6897932*T + <i>GPR65</i> rs2119704*C + <i>SOX8</i> rs2744148*G	0.15	0.06	3.00	1.72–5.25	3.71x10 <sup>-5</sup>	2.45x10 <sup>-4</sup>
<i>INAVA</i> rs7522462*A + <i>MANBA</i> rs228614*A/G + <i>SOX8</i> rs2744148*G	0.08	0.03	3.00	1.39–6.45	2.43x10 <sup>-3</sup>	7.28x10 <sup>-3</sup>
<i>INAVA</i> rs7522462*G + <i>C6orf10</i> rs3129934*C + <i>SOX8</i> rs2744148*A	0.77	0.91	0.31	0.18–0.52	1.98x10 <sup>-6</sup>	2.82x10 <sup>-5</sup>
<i>INAVA</i> rs7522462*G + <i>C6orf10</i> rs3129934*C	0.81	0.93	0.30	0.17–0.54	1.47x10 <sup>-5</sup>	1.21x10 <sup>-4</sup>
<i>CD86</i> rs9282641*G + <i>C6orf10</i> rs3129934*C + <i>SOX8</i> rs2744148*A	0.88	0.97	0.24	0.11–0.52	6.94x10 <sup>-5</sup>	3.96x10 <sup>-4</sup>
<i>C6orf10</i> rs3129934*C	0.94	0.99	0.20	0.08–0.47	8.04x10 <sup>-5</sup>	4.41x10 <sup>-4</sup>
<b>Men</b>						
<i>EOMES</i> rs11129295*C + <i>C6orf10</i> rs3129934*T + <i>RPS6KB1</i> rs180515*C	0.27	0.10	3.25	1.92–5.48	8.76x10 <sup>-6</sup>	0.014
<i>C6orf10</i> rs3129934*T + <i>RPS6KB1</i> rs180515*C + <i>CD40</i> rs6074022*T	0.31	0.13	3.00	1.83–4.90	1.03x10 <sup>-5</sup>	0.011
<i>EOMES</i> rs11129295*C + <i>PVT1</i> rs4410871*T + <i>GPR65</i> rs2119704*A	0.01	0.08	0.14	0.03–0.58	6.630x10 <sup>-4</sup>	0.013

sclerosis of the five variants (*INAVA* rs7522462, *EOMES* rs11129295, *C6orf10* rs3129934, *CD86* rs9282641, and *GPR65* rs2119704) identified earlier in genome-wide scans. The strongest association was detected for the rs3129934 polymorphism located in the MHC region. The lack of association for the rest of the tested SNPs may be due to the limited sample size and the population admixture. However, this is the largest study of multiple sclerosis in Russian population conducted to date (641 patients and 1407 unaffected individuals), and the study group was formed taking into account the ethnic origin of the participants. Using multilocus approach, we were able to identify complex markers of MS that may reflect the interindividual differences in predisposition to MS. Future endeavours implementing approaches such as whole genome-sequencing or exome-sequencing may help further elucidate mechanisms underlying the development of MS in these three ethnic populations.

## Funding

The research was supported by the Russian Foundation for Basic Research grants [19-54-40007 and 17-44-020735] and the megagrant of the Government of Russian Federation [075-15-2021-595].

## CRediT authorship contribution statement

**YT:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. **TRN:** Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Writing – review & editing. **IAT:** Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision. **VVE:** Data curation, Investigation. **TRG, OVZ:** Data curation, Investigation, Project administration. **KZB:** Investigation, Supervision, Project administration.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence

the work reported in this paper.

## Acknowledgements

The authors thank all the physicians and patients who contributed to the study.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.gene.2021.146008>.

## References

- Andlauer TFM, Buck D, Antony G, et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. *Sci Adv* 2016; 2: e1501678–e1501678. 10.1126/sciadv.1501678.
- Bahlo, M., Booth, D.R., Broadley, S.A., et al., 2009. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. *Nat. Genet.* 41, 824–828. <https://doi.org/10.1038/ng.396>.
- Beecham, A.H., Patsopoulos, N.A., Xifara, D.K., et al., 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat. Genet.* 45, 1353–1360. <https://doi.org/10.1038/ng.2770>.
- Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B (Methodological)* 289–300. <https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>.
- Berghoff, S.A., Gerndt, N., Winchenbach, J., et al., 2017. Dietary cholesterol promotes repair of demyelinated lesions in the adult brain. *Nat. Commun.* 8, 14241. <https://doi.org/10.1038/ncomms14241>.
- Browne, P., Chandraratna, D., Angood, C., et al., 2014. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. *Neurology* 83, 1022–1024. <https://doi.org/10.1212/WNL.0000000000000768>.
- Chen, S., Zhang, J., Liu, Q.-B., et al., 2018. Variant of *EOMES* Associated with Increasing Risk in Chinese Patients with Relapsing-remitting Multiple Sclerosis. *Chin. Med. J.* 131, 643–647. <https://doi.org/10.4103/0366-6999.226892>.
- Comabella, M., Craig, D.W., Camina-Tato, M., et al., 2008. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. *PLoS ONE* 3, e3490. <https://doi.org/10.1371/journal.pone.0003490>.
- Corradin, O., Cohen, A.J., Luppino, J.M., et al., 2016. Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry. *Nat. Genet.* 48, 1313.
- Cortes A, Hadler J, Pionton JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* 2013; 45: 730–738. 2013/06/12. 10.1038/ng.2667.

- Cree, B.A.C., Khan, O., Bourdette, D., Goodin, D.S., Cohen, J.A., Marrie, R.A., Glidden, D., Weinstock-Guttman, B., Reich, D., Patterson, N., Haines, J.L., Pericak-Vance, M., DeLoa, C., Oksenberg, J.R., Hauser, S.L., 2004. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. *Neurology* 63 (11), 2039–2045.
- De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. *Nat Genet* 2009; 41: 776–782. 2009/06/16. 10.1038/ng.401.
- Favorov, A.V., Andreewski, T.V., Sudomoina, M.A., et al., 2005. A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. *Genetics* 171, 2113–2121. <https://doi.org/10.1534/genetics.105.048090>.
- Fraussen, J., Claes, N., Van Wijmeersch, B., et al., 2016. B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. *Clin Immunol* 173, 124–132. <https://doi.org/10.1016/j.clim.2016.10.001>.
- G. B. D. Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 2019; 18: 269–285. 2019/01/27. 10.1016/S1474-4422(18)30443-5.
- Gruarin, P., Maglie, S., De Simone, M., et al., 2019. Eomesodermin controls a unique differentiation program in human IL-10 and IFN- $\gamma$  coproducing regulatory T cells. *Eur. J. Immunol.* 49, 96–111. <https://doi.org/10.1002/eji.201847722>.
- Guan, H., Guo, Y., Liu, L., et al., 2018. INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression. *Cell & Bioscience* 8, 26. <https://doi.org/10.1186/s13578-018-0224-4>.
- Hafler, D.A., Compston, A., Sawcer, S., et al., 2007. Risk alleles for multiple sclerosis identified by a genomewide study. *N. Engl. J. Med.* 357, 851–862. <https://doi.org/10.1056/NEJMoa073493>.
- Iannetta, M., Zingaropoli, M.A., Latronico, T., et al., 2019. Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. *Sci. Rep.* 9, 311. <https://doi.org/10.1038/s41598-018-36535-5>.
- Jakkula, E., Leppä, V., Sulonen, A.M., et al., 2010. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. *Am. J. Hum. Genet.* 86, 285–291. <https://doi.org/10.1016/j.ajhg.2010.01.017>.
- Liuzzi, G.M., Trojano, M., Fanelli, M., et al., 2002. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. *Multiple Sclerosis Journal* 8, 222–228. <https://doi.org/10.1191/1352458502ms800oa>.
- Martinelli-Boneschi F, Esposito F, Brambilla P, et al. A genome-wide association study in progressive multiple sclerosis. *Mult Scler* 2012; 18: 1384–1394. 2012/03/30. 10.1177/1352458512439118.
- McKay, F.C., Gatt, P.N., Fewings, N., et al., 2016. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. *Clin Immunol* 163, 96–107. <https://doi.org/10.1016/j.clim.2015.12.015>.
- Mohan, H., Friesse, A., Albrecht, S., et al., 2014. Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. *Acta Neuropathologica Communications* 2, 178. <https://doi.org/10.1186/s40478-014-0168-9>.
- Nischwitz, S., Cepok, S., Kroner, A., et al., 2010. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. *J. Neuroimmunol.* 227, 162–166. <https://doi.org/10.1016/j.jneuroim.2010.06.003>.
- Parnell, G.P., Gatt, P.N., Krupa, M., et al., 2014. The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. *Clin Immunol* 151, 16–24. <https://doi.org/10.1016/j.clim.2014.01.003>.
- Patsopoulos NA, Esposito F, Reischl J, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. *Ann Neurol* 2011; 70: 897–92011/12/23. 10.1002/ana.22609.
- Patsopoulos NA, Baranzini SE, Santaniello A, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science* 2019; 365: 1417–+. 2019/10/110.1126/science.aav7188.
- Purcell, S., Neale, B., Todd-Brown, K., et al., 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 81, 559–575. <https://doi.org/10.1086/519795>.
- Reiser, J., Sadashivaiah, K., Furusawa, A., et al., 2019. Eomesodermin driven IL-10 production in effector CD8+ T cells promotes a memory phenotype. *Cell. Immunol.* 335, 93–102. <https://doi.org/10.1016/j.cellimm.2018.11.008>.
- Sanna, S., Pitzalis, M., Zoledziwska, M., et al., 2010. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. *Nat. Genet.* 42, 495–497. <https://doi.org/10.1038/ng.584>.
- Sastre-Garriga, J., Comabella, M., Brieve, L., et al., 2004. Decreased MMP-9 production in primary progressive multiple sclerosis patients. *Multiple Sclerosis Journal* 10, 376–380. <https://doi.org/10.1191/1352458504ms1058oa>.
- International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011; 476: 214–219. 10.1038/nature10251.
- Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011; 476: 214–219. 2011/08/13. 10.1038/nature10251.
- Smets, I., Fiddes, B., Garcia-Perez, J.E., et al., 2018. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. *Brain* 141, 786–796.
- Yan, J., Hedl, M., Abraham, C., 2017. An inflammatory bowel disease–risk variant in INAVA decreases pattern recognition receptor–induced outcomes. *J. Clin. Investig.* 127, 2192–2205. <https://doi.org/10.1172/JCI86282>.
- Yates, A.D., Achuthan, P., Akanni, W., et al., 2019. Ensembl 2020. *Nucleic Acids Res.* 48, D682–D688. <https://doi.org/10.1093/nar/gkz966>.